News headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.8565399784513 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern’s scoring:

SPPI has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Spectrum Pharmaceuticals in a research note on Monday, December 18th. B. Riley initiated coverage on Spectrum Pharmaceuticals in a research note on Monday, December 18th. They set a “buy” rating and a $26.00 target price on the stock. Guggenheim initiated coverage on Spectrum Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $32.00 target price on the stock. Jefferies Group lifted their target price on Spectrum Pharmaceuticals to $25.00 and gave the stock a “buy” rating in a research note on Friday, October 20th. Finally, Zacks Investment Research upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 12th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Spectrum Pharmaceuticals has an average rating of “Buy” and an average target price of $22.17.

Shares of Spectrum Pharmaceuticals (SPPI) opened at $18.83 on Friday. Spectrum Pharmaceuticals has a 52 week low of $4.31 and a 52 week high of $21.95. The stock has a market capitalization of $1,900.00, a PE ratio of -18.83 and a beta of 1.63. The company has a quick ratio of 4.89, a current ratio of 5.04 and a debt-to-equity ratio of 0.33.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.06). Spectrum Pharmaceuticals had a negative net margin of 58.94% and a negative return on equity of 29.73%. The firm had revenue of $36.40 million during the quarter, compared to the consensus estimate of $33.27 million. During the same quarter in the prior year, the firm posted ($0.07) earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. equities analysts anticipate that Spectrum Pharmaceuticals will post -1.06 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Spectrum Pharmaceuticals (SPPI) Receives Daily Media Sentiment Rating of 0.13” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at

Spectrum Pharmaceuticals Company Profile

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Insider Buying and Selling by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with's FREE daily email newsletter.